

Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19

Lucija Klaric^{1*}, Jack S. Gisby^{2*}, Artemis Papadaki^{2*}, Marisa D. Muckian³, Erin Macdonald-Dunlop³, Jing Hua Zhao⁴, Alex Tokolyi⁵, Elodie Persyn⁴, Erola Pairo-Castineira^{6,1}, Andrew P Morris⁷, Anette Kalnapekis⁸, Anne Richmond¹, Arianna Landini³, Åsa K. Hedman^{9,10}, Bram Prins⁴, Daniela Zanetti¹¹, Eleanor Wheeler¹², Charles Kooperberg¹³, Chen Yao^{14,15}, John R. Petrie¹⁶, Jingyuan Fu^{17,18}, Lasse Folkersen¹⁹, Mark Walker²⁰, Martin Magnusson^{21,22,23}, Niclas Eriksson²⁴, Niklas Mattsson-Carlsson^{25,26,22}, Paul R.H.J. Timmers^{1,3}, Shih-Jen Hwang^{14,15}, Stefan Enroth²⁷, Stefan Gustafsson²⁸, Urmo Vosa⁸, Yan Chen^{9,29}, Agneta Siegbahn²⁸, Alexander Reiner¹³, Åsa Johansson²⁷, Barbara Thorand^{30,31}, Bruna Gigante³², Caroline Hayward¹, Christian Herder^{33,34,31}, Christian Gieger^{30,35,31}, Claudia Langenberg^{12,36,37}, Daniel Levy^{14,15}, Daria V. Zhernakova^{17,38}, J. Gustav Smith^{39,40,22,41,42,43}, Harry Campbell³, Johan Sundstrom^{28,44}, John Danesh^{4,37,5}, Karl Michaëlsson⁴⁵, Karsten Suhre⁴⁶, Lars Lind²⁸, Lars Wallentin^{28,47}, Leonid Padyukov^{48,49}, Mikael Landén^{29,50}, Nicholas J. Wareham^{12,37}, Andreas Göteson⁵⁰, Oskar Hansson^{25,51}, Per Eriksson^{32,49}, Rona J. Strawbridge^{52,37,32}, Themistocles L. Assimes^{11,53}, Tonu Esko⁸, Ulf Gyllenstein²⁷, J. Kenneth Baillie^{54,6,1}, Dirk S. Paul^{4,55,56}, Peter K. Joshi³, Adam S. Butterworth^{4,37,56}, Anders Mälarstig^{29,10}, Nicola Pirastu³, James F. Wilson^{1,3*}, James E. Peters^{2,37*}

Affiliations

1 MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, UK

2 Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK

3 Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh, UK

4 British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

5 Department of Human Genetics, Wellcome Sanger Institute, Hinxton, UK

6 Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, UK

7 Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK

8 Institute of Genomics, University of Tartu, 51010, Estonia

9 Department of Medicine, Karolinska Institute, Stockholm, Sweden

10 Pfizer Worldwide Research, Development and Medical, Sweden

11 Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

12 MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK

13 Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

14 Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA

15 Framingham Heart Study, Framingham, MA, USA.

16 Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK

17 Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

18 Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

19 Danish National Genome Center, Copenhagen, Denmark

20 Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

21 Department of Clinical Sciences, Lund University, Malmö, Sweden

22 Wallenberg Center for Molecular Medicine, Lund University, Sweden

23 Hypertension in Africa Research Team (HART), North West University, Potchefstroom, South Africa

24 Uppsala Clinical Research Center (UCR), Uppsala University, Uppsala, Sweden

25 Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden

26 Department of Neurology, Skåne University Hospital, Lund University, Lund, Sweden

27 Department of Immunology, Genetics and Pathology, Uppsala University, Sweden

28 Department of Medical Sciences, Uppsala University, Uppsala, Sweden

29 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

30 Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, München-Neuherberg, Germany

31 German Center for Diabetes Research (DZD), München-Neuherberg, Germany

32 Division of Cardiovascular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

33 Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany

34 Division of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

62 35 Research Unit of Molecular Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health,
63 Neuherberg, Germany
64 36 Computational Medicine, Berlin Institute of Health (BIH) at Charité – Universitäts Medizin Berlin, Germany
65 37 Health Data Research UK, Wellcome Genome Campus and University of Cambridge, Cambridge, UK
66 38 Laboratory of Genomic Diversity, Center for Computer Technologies, ITMO University, St. Petersburg, Russia
67 39 Department of Cardiology, Clinical Sciences, Lund University
68 40 Skåne University Hospital, Lund, Sweden
69 41 Lund University Diabetes Center, Lund University, Lund, Sweden
70 42 The Wallenberg Laboratory/Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University
71 43 Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden
72 44 The George Institute for Global Health, University of New South Wales, Sydney, Australia
73 45 Department of Surgical Sciences, Unit of Medical Epidemiology, Uppsala University, Uppsala, Sweden
74 46 Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Doha, Qatar
75 47 Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
76 48 Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Sweden
77 49 Karolinska University Hospital, Stockholm, Sweden
78 50 Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
79 51 Memory Clinic, Skåne University Hospital, Malmö, Sweden
80 52 Institute of Health and Wellbeing, College of Medicine, Veterinary and Life Sciences, University of Glasgow, UK
81 53 Palo Alto VA Healthcare System, Palo Alto, CA, USA
82 54 Intensive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK
83 55 British Heart Foundation Centre of Research Excellence, Addenbrookes Hospital, Cambridge, UK
84 56 National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of
85 Cambridge, Cambridge, United Kingdom
86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102 *Authors contributed equally. Correspondence to J.F.W. (jim.wilson@ed.ac.uk) or J.E.P.

103 (j.peters@imperial.ac.uk)

104

105

106 **Abstract**

107
108 Severe COVID-19 is characterised by immunopathology and epithelial injury. Proteomic studies
109 have identified circulating proteins that are biomarkers of severe COVID-19, but cannot
110 distinguish correlation from causation. To address this, we performed Mendelian randomisation
111 (MR) to identify proteins that mediate severe COVID-19. Using protein quantitative trait loci
112 (pQTL) data from the SCALLOP consortium, involving meta-analysis of up to 26,494 individuals,
113 and COVID-19 genome-wide association data from the Host Genetics Initiative, we performed
114 MR for 157 COVID-19 severity protein biomarkers. We identified significant MR results for five
115 proteins: FAS, TNFRSF10A, CCL2, EPHB4 and LGALS9. Further evaluation of these candidates
116 using sensitivity analyses and colocalization testing provided strong evidence to implicate the
117 apoptosis-associated cytokine receptor FAS as a causal mediator of severe COVID-19. This
118 effect was specific to severe disease. Using RNA-seq data from 4,778 individuals, we
119 demonstrate that the pQTL at the *FAS* locus results from genetically influenced alternate splicing
120 causing skipping of exon 6. We show that the risk allele for very severe COVID-19 increases the
121 proportion of transcripts lacking exon 6, and thereby increases soluble FAS. Soluble FAS acts as
122 a decoy receptor for FAS-ligand, inhibiting apoptosis induced through membrane-bound FAS. In
123 summary, we demonstrate a novel genetic mechanism that contributes to risk of severe of
124 COVID-19, highlighting a pathway that may be a promising therapeutic target.

125
126 **Main**

127
128 Severe COVID-19 is characterised by exaggerated inflammatory responses and
129 immunopathology¹⁻⁴. The two pharmacological treatments that have robustly demonstrated
130 efficacy in reducing risk for severe COVID-19 in randomised clinical trials to date are
131 glucocorticoids and interleukin 6 (IL-6) receptor blockade⁵⁻⁷. Treatments directed at the
132 inflammatory response thus represent the most promising therapeutic strategy. A wide range of
133 therapies directed at specific elements of the inflammatory response have been developed for
134 autoimmune and inflammatory diseases^{8,9}, and present potential repurposing opportunities for
135 treatment of COVID-19. Profiling of plasma proteins in COVID-19 patients has revealed a
136 signature of innate immune cell activation (including upregulation of IL-6, monocyte chemokines
137 and neutrophil proteins) and epithelial/endothelial injury in severe disease^{10,11}. A limitation of such
138 observational studies, however, is that they cannot distinguish causal mediators of
139 immunopathology from secondary downstream consequences of inflammation and/or tissue

140 injury. Bridging this knowledge gap is critical for prioritising therapeutic targets and triaging
141 medicines for clinical trials.

142

143 Making causal inference from human observational data is challenging due to confounding and
144 reverse causation. Mendelian randomisation (MR) is an analytical approach that can circumvent
145 these difficulties. MR enables causal inference by leveraging the random allocation of alleles at
146 meiosis, which effectively provides a natural randomised trial^{12,13}. MR tests whether there is a
147 causal relationship between an exposure (e.g. a molecular trait) and an outcome (e.g. a clinical
148 phenotype) using genetic variants as ‘instruments’. If a genetic variant associated with the
149 exposure is also associated with the outcome, this provides evidence of a putatively causal
150 relationship between the two. Using proteins as exposures in MR analyses has several
151 advantages. First, proteins are gene products and as such are under greater genetic control than
152 downstream phenotypes. Second, proteins are the targets of most drugs and so MR using
153 proteins can identify and prioritise promising therapeutic targets. MR using proteins is now
154 increasingly possible because of large genome-wide association studies (GWAS) that have
155 identified genetic variants associated with levels of circulating proteins (protein quantitative trait
156 loci, pQTL)¹⁴⁻¹⁶.

157

158 Here, we performed MR analysis to test whether proteins observationally associated with COVID-
159 19 severity play a causal role in critical illness from COVID-19, using pQTL identified through a
160 meta-analysis of up to 26,494 individuals. Our results implicate the cytokine receptor FAS as
161 playing a putatively causal role in severe COVID-19. We demonstrated the robustness of this
162 result using a range of sensitivity analyses and colocalisation analysis, and we replicated it using
163 an independent pQTL dataset. The pQTL for FAS in the *FAS* gene region could not be explained
164 by a corresponding expression quantitative trait locus (eQTL). We therefore examined mRNA
165 splicing events in whole blood RNA-seq data from 4,778 individuals. This revealed that the pQTL
166 for FAS in the *FAS* gene region is mediated by genetically influenced alternative splicing, resulting
167 in skipping of exon 6 and affecting the ratio of soluble to membrane-bound FAS. We thus
168 demonstrate a novel genetic mechanism contributing to risk of severe COVID-19 via a splice QTL
169 (sQTL). We hypothesise that modulating the FAS pathway may therefore be a promising
170 therapeutic strategy.


171

172 **Results**

173

174 We first identified a list of proteins associated with COVID-19 clinical severity grading by
 175 examining two studies that performed broad proteomic profiling of COVID-19 patient plasma
 176 samples using the Olink proteomics platform^{10,11}. We took the lists of severity-associated proteins
 177 from each study (Benjamini-Hochberg adjusted $P < 0.05$) and intersected these to provide a high-
 178 confidence list of 157 severity-associated proteins (**Fig. 1**). To evaluate whether these proteins
 179 play a causal role in severe COVID-19, we performed two-sample Mendelian randomisation
 180 analysis.

181



182
 183 **Figure 1:** Mendelian randomisation study design and data sources. Severity-associated protein
 184 biomarkers were identified from the studies by Filbin *et al.*¹⁰ and Gisby *et al.*¹¹.

185
 186
 187 To identify genetic instruments for MR, we accessed data from large European-heritage meta-
 188 analyses of plasma pQTL studies that also used the Olink platform performed by the SCALLOP
 189 consortium (<https://www.olink.com/scallop/>)¹⁵. The sample sizes of the protein GWAS meta-

190 analyses varied from 3,658 to 26,494 (**Methods**). MR analysis was possible for 140 proteins,
191 where at least one non-HLA pQTL was available. For 30 proteins there were only local-acting
192 ('cis') pQTL (i.e., the pQTL lies within +/-0.5 Mb of the gene encoding the protein), for 17 there
193 were only distant-acting ('trans') pQTL, and for 93 there were both. At each pQTL, we performed
194 linkage disequilibrium pruning ($LD\ r^2 \leq 0.01$) to remove correlated variants, prior to MR (**Methods**).

195

196 For the outcome data, we used GWAS summary statistics from the COVID-19 Host Genetics
197 Initiative release 5 (HGI: <https://www.covid19hg.org>)¹⁷ for very severe respiratory COVID-19
198 (defined as hospitalised patients requiring respiratory support and/or who died (analysis A2); for
199 brevity, hereafter referred to as 'severe COVID-19').

200

201 We identified five proteins, EPH receptor B4 (EPHB4), C-C motif chemokine ligand 2 (CCL2),
202 galectin 9 (LGALS9), Tumour Necrosis Factor Receptor Superfamily Member 10A (TNFRSF10A)
203 and Fas cell surface death receptor (FAS), with significant MR causal estimates for severe
204 COVID-19 after multiple testing correction (5% false discovery rate (FDR)) (**Table 1**).

205

206 An important assumption of MR is that genetic instruments (here pQTL) affect the outcome (here
207 severe COVID-19) only through the exposure (here the protein), and not through observed or
208 non-observed confounding factors (the 'no horizontal pleiotropy' assumption)^{18,19}. We therefore
209 used a multi-layered strategy to assess whether our results were robust (**Methods, Fig. 1**). First,
210 we used heterogeneity tests to test whether there was consistency in the causal effect estimates
211 across the genetic variants used. Second, we performed sensitivity analyses using alternative MR
212 methods that are robust to horizontal pleiotropy, including MR Egger, weighted mode and median
213 methods. Third, we performed MR restricting genetic instruments to cis-pQTL. Finally, we used
214 colocalization to test whether the pQTL and severe COVID-19 genetic association signals
215 reflected the same or distinct underlying causal variants.

216

217 For 3 proteins (EPHB4, FAS and TNFRSF10A) there was no heterogeneity in effect estimates
218 between individual genetic variants, and effect estimates of pleiotropy-robust methods were
219 similar to those of the inverse-variance method. In contrast, for LGALS9 and CCL2, we observed
220 significant heterogeneity (Cochran's $Q > 50$ and heterogeneity p-value < 0.05) (**Table 1**,
221 **Supplementary Fig. 1a**), casting doubt on the reliability of the causal inference for these two
222 proteins.

223

224 Cis protein quantitative trait loci (cis-pQTL), genetic variants that lie near the gene encoding the
 225 affected protein, are considered to be more reliable MR instruments since their direct relationship
 226 with the protein means they are less likely to violate the ‘no horizontal pleiotropy’ assumption than
 227 trans-pQTL, which may act through indirect pathways²⁰. Therefore, as an additional sensitivity
 228 analysis, we tested whether we observed consistent causal effects when limiting genetic
 229 instruments to cis-pQTL. This cis-only MR analysis revealed significant results for FAS ($P 6.7 \times 10^{-4}$)
 230 and TNFRSF10A ($P 1.9 \times 10^{-3}$), but not EPHB4, CCL2 or LGALS9 ($P > 0.1$); **Table 1**,
 231 **Supplementary Fig. 1b**.

232
 233

234 **Table 1:** Mendelian Randomisation of COVID-19 severity-associated circulating proteins and risk
 235 of severe COVID-19.

Protein*	# IV	MR P	FDR	OR (95% CI)	cis OR (95% CI)	cis P	Cochran's Q (p-value)	Egger Intercept P
EPHB4	5	1.28×10^{-6}	1.69×10^{-4}	0.56 (0.44-0.71)	0.64 (0.36-1.15)	0.13	4.3 (0.36)	0.90
CCL2	7	2.43×10^{-6}	1.69×10^{-4}	1.54 (1.29-1.84)	0.71 (0.26-1.92)	0.50	97.0 (1.1×10^{-18})	0.98
LGALS9	26	6.38×10^{-4}	2.96×10^{-2}	0.79 (0.69-0.91)	0.90 (0.78-1.04)	0.16	54.7 (5.4×10^{-4})	0.05
TNFRSF10A	28	1.71×10^{-3}	4.76×10^{-2}	0.81 (0.71-0.92)	0.81 (0.71-0.92)	1.91×10^{-3}	9.4 (0.36)	0.03
FAS	7	1.36×10^{-3}	4.74×10^{-2}	1.40 (1.14-1.72)	1.44 (1.17-1.78)	6.70×10^{-4}	29.1 (0.15)	0.05


IV - number of instruments used; MR P – Inverse-variance fixed effect MR p-value; FDR – Benjamini-Hochberg adjusted MR p-value; OR – odds ratio; cis OR – odds ratio using cis-only variants; cis P – Inverse-variance fixed effect p-value for cis-only MR analysis; Cochran's Q – inverse-variance weighted heterogeneity Cochran's Q and p-value; Egger Intercept p – p-value of the Egger intercept.

*Proteins annotated using the symbols of the encoding gene. EPHB4 - Ephrin type-B receptor 4; CCL2 - C-C motif chemokine 2; LGALS9 - Galectin-9; TNFRSF10A - Tumor necrosis factor receptor superfamily member 10A; FAS – FAS (also known as Tumor necrosis factor receptor superfamily member 6).

236
 237

238 Next, to disentangle causal relationships from confounding by linkage disequilibrium, we
 239 performed colocalisation analysis²¹ at each locus to test whether the same causal variant
 240 underlies the pQTL and the association with severe COVID-19. For the cis-pQTL for FAS, there
 241 was convincing colocalisation of the pQTL and the severe COVID-19 signal (posterior probability
 242 (PP) of shared causal variant 0.95) (**Fig. 2a**). In contrast, for the cis-pQTL for TNFRSF10A, it was
 243 clear that the pQTL and the disease association were driven by different causal variants (PP of
 244 distinct causal variants 0.87, **Supplementary Fig. 2a**). Thus, we have evidence to support a
 245 causal role for FAS, but not TNFRSF10A, in severe COVID-19.

246



247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270

Figure 2: Mendelian Randomisation (MR) of soluble FAS protein levels and COVID-19 outcomes.

a) Regional association plot (hg19 genome build) showing the cis-pQTL for soluble FAS (plasma) and the associations with COVID-19 outcomes. Posterior probability of a shared causal variant (PP H4) between FAS protein levels and very severe COVID-19 = 0.95.

b) MR estimates of the causal effect of soluble FAS protein on different COVID-19 outcomes: susceptibility to infection, hospitalisation and very severe disease.

c) Soluble FAS protein levels in COVID-19 patients, stratified by clinical severity, and non-infected controls (data from Gisby *et al.*¹¹). Boxplots showing distribution of plasma protein levels according to COVID-19 status at the time of blood draw. Boxplots indicate median and interquartile range. n=256 samples from 55 COVID-19 patients and 51 samples from non-infected patients. ‘COVID-19 status’ indicates clinical severity score of the patient at the time the sample was taken. Mild n=135 samples; moderate n=77 samples; severe n=29 samples; critical n= 15 samples.

To empirically evaluate whether there was evidence of horizontal pleiotropy, we examined whether the cis genetic instruments for FAS used in the MR analysis, or variants in LD with them ($r^2 > 0.6$), were associated with any protein. We utilised the PhenoScanner database that contains >5,000 genotype-phenotype associations^{22,23} and found no other associations with other proteins (at $P < 1 \times 10^{-5}$).

271 To validate our results, we repeated the two-sample MR for soluble FAS in severe COVID-19
272 using genetic instruments derived from an independent pQTL dataset from a study using an
273 alternative proteomics platform, the aptamer-based Somascan¹⁴. Consistent with our primary
274 analysis, this revealed that genetic predisposition to higher circulating soluble FAS levels is
275 associated with increased risk of severe COVID-19 (MR estimate OR = 1.35 [95% CI 1.14-1.60],
276 p-value = 4.6×10^{-4}) (**Supplementary Fig. 3**), providing independent support for our findings.

277
278 Having established evidence for a putatively causal role for FAS in severe COVID-19, we asked
279 whether it may also play a role in susceptibility to COVID-19. We repeated the MR analysis using
280 different COVID-19 GWAS datasets: all individuals with COVID-19 versus controls (i.e.
281 susceptibility to COVID-19 – HGI C2 analysis), and all hospitalised COVID-19 patients vs controls
282 (i.e. selecting for a degree of severity – HGI B2 analysis). Strikingly, we saw a gradient of MR
283 effects across these outcomes. FAS showed no causal effect on susceptibility to COVID-19, a
284 weak effect on COVID-19 hospitalisation and strong effect on severe COVID-19 (**Fig. 2b**). These
285 data suggest that genetic propensity to higher soluble FAS levels influences COVID-19 severity,
286 but not susceptibility. Observational data from the analysis of Gisby *et al.*¹¹ revealed a similar
287 pattern. Plasma FAS was not significantly differentially abundant in the comparison of all COVID-
288 19 cases versus uninfected controls (Benjamini-Hochberg adjusted P value 0.280), but it was
289 highly significantly associated with COVID-19 severity grading within-cases (Benjamini-Hochberg
290 adjusted P 0.019) (**Fig. 2c**).


291
292 We next investigated the mechanism underlying the cis-pQTL for plasma FAS. The most strongly
293 associated pQTL variant for FAS was rs982764 (**Supplementary Table 1**), an intronic single
294 nucleotide polymorphism (SNP) in *FAS*, located between exons 4 and 5. This is a common
295 variant, with minor allele frequency (MAF) ~31% in European ancestry individuals. The major
296 allele, rs982764:T, was associated with higher circulating soluble FAS levels and higher risk of
297 severe COVID-19 (**Supplementary Fig. 4**). The sentinel variant, rs982764, was not in LD (r^2
298 >0.2) with any non-synonymous protein-coding variants. We therefore evaluated whether the
299 pQTL was mediated through regulation of gene expression by examining eQTL data from the
300 GTEx Catalogue (multiple tissues), whole-blood data from eQTLGen²⁴, and sorted immune cell
301 subsets from Peters *et al.*²⁵. While these data revealed a cis-eQTL for FAS that was common to
302 multiple tissues (e.g. lung, whole-blood, monocytes, adipose tissue, and artery), the eQTL signal
303 did not colocalise with the pQTL (PP of distinct causal variants of 1.00 for both eQTLGen and
304 GTEx) (**Supplementary Fig. 5**). Since the results of colocalisation methods can be affected by

305 the presence of multiple independent variants, we then performed colocalisation using a method
306 that allows for multiple causal variants (SuSiE²⁶). This confirmed that, even after accounting for
307 conditionally independent signals, the eQTL signal and pQTL signals for FAS did not colocalise
308 (PP of distinct causal variants = 1.00).

309
310 Given that the pQTL could not be explained by an eQTL, we hypothesised that it might arise due
311 to genetically influenced alternative splicing. FAS is a receptor for the cytokine FASL-ligand
312 (FASL), and binding of FASL to FAS on the cell surface triggers an intracellular signalling cascade
313 that leads to apoptosis of the cell. In humans, the *FAS* gene has 9 exons and encodes a cell
314 surface receptor consisting of an extracellular portion, a transmembrane domain and an
315 intracellular portion. In addition to the full-length *FAS* mRNA, several shorter transcripts arising
316 from alternative splicing have been described (**Fig. 3a**)^{27,28}. Alternative splicing leading to
317 skipping of exon 6 (transcript isoform *FAS*Δ*Ex6*) results in a secreted protein lacking the
318 transmembrane domain²⁸. This soluble form of FAS acts as a decoy receptor for FASL and thus
319 has biologically opposing actions to membrane-bound FAS by reducing FAS-FASL signalling,
320 resulting in reduced apoptosis²⁹.

321
322 We therefore tested the hypothesis that the pQTL for plasma FAS resulted from genetically
323 regulated skipping of exon 6. Using whole-blood RNA-seq data from 4,778 individuals, we
324 examined alternative splicing and tested for associations between variants in the *FAS* region and
325 transcripts lacking exon 6. The sentinel pQTL SNP, rs982764, was strongly associated with exon
326 6 skipping ($P = 2.1 \times 10^{-22}$). Moreover, the exon 6 splice QTL displayed the same association
327 pattern as the pQTL and the GWAS signal for very severe COVID-19 (**Fig. 3a**). Formal
328 colocalisation analysis confirmed that the splice QTL and the pQTL were highly likely to reflect
329 the same underlying causal variant (PP of shared causal variant of 0.998). The risk allele for
330 severe COVID-19 (rs982764:T) was associated with a shift towards transcripts lacking exon 6,
331 which are known to encode soluble FAS (**Fig. 3b**). We confirmed this empirically via our pQTL
332 data, with rs982764:T associated with higher plasma soluble FAS abundance. Together these
333 data reveal a novel genetic mechanism by which a non-coding variant impacts the risk of severe
334 COVID-19 through alternative splicing leading to elevated soluble FAS.

335



337 **Figure 3: a)** Regional association plot showing (from top to bottom): transcript isoforms, the
338 soluble FAS cis-pQTL, and the associations with FAS exon 6 splicing. *FASΔEx6* indicates the
339 transcript isoform lacking exon 6 (red circle). The posterior probability of a shared causal variant
340 (PP H4) between FAS protein levels and exon 6 splicing = 0.99.

341 **b)** Boxplot showing exon 6 splice quantitative trait locus (sQTL). Number of individuals by
342 genotype at rs982764: 443 (CC), 1992 (CT), 2329 (TT). In 14 individuals genotype could not be
343 reliably ascertained. Y-axis represents % of transcripts with exon 6 skipping. P for association
344 with genotype 4×10^{-22} (linear model).

345 **c)** Proposed model by which genetic variation in *FAS* increases risk of severe COVID-19. A non-
346 coding variant acts as a splice QTL. The risk allele for very severe COVID-19 (rs982764:T) is
347 associated with an increased proportion of transcripts lacking exon 6 resulting in higher levels of
348 soluble FAS (sFAS). sFAS acts as a decoy receptor for FAS-ligand (FASL), blocking FASL
349 binding to membrane-bound FAS (mFAS) on the cell surface and thus reducing apoptosis.

350

351

352 Discussion

353

354 Here we performed Mendelian Randomisation (MR) to evaluate whether proteins observationally
355 associated with severe COVID-19 play a causal role in severe disease. We focused on severe
356 COVID-19 as this is responsible for the loss of life and has threatened to overcome the capacity
357 of healthcare systems across the world. In addition to vaccination programmes, there is an urgent
358 need for therapies to ameliorate severe disease. This requires improved understanding of the
359 aberrant host immune response in this subset of patients.

360

361 We took a broad, but hypothesis-driven approach, by focussing on proteins that have been shown
362 to robustly associate observationally with disease severity in COVID-19 patients in two
363 independent clinical cohorts. A strength of our study was the use of a large-scale pQTL meta-
364 analyses to provide robust genetic instruments. Our MR analysis revealed that the genetic
365 tendency to higher plasma soluble FAS increased the risk of very severe COVID-19, implicating
366 soluble FAS as a causal factor in severe COVID-19. Using a range of COVID-19 patient severity
367 phenotypes (any diagnosis of COVID-19 infection, hospitalisation due to COVID-19, and very
368 severe COVID-19 requiring respiratory support) in our MR analyses revealed a gradient of causal
369 effect size estimates proportional to COVID-19 severity (**Fig. 2b**). These data suggest that the
370 FAS pathway plays a role specifically in the pathogenesis of severe disease, rather than
371 susceptibility to COVID-19 infection. Examination of soluble FAS levels in the plasma of patients
372 with COVID-19 revealed a similar pattern (**Fig. 2c**).

373

374 The *FAS* gene encodes the FAS death receptor, also known as tumour necrosis factor receptor
375 superfamily member 6 (TNFRSF6). Alternative splicing leads to multiple transcript isoforms (**Fig.**

376 **3a)**^{27,28}. The canonical isoform encodes a type 1 transmembrane protein that is the cell surface
377 receptor for the cytokine FAS-ligand (FASL), and plays important roles in the control of apoptosis,
378 particularly in lymphocytes³⁰. Binding of FASL to the extracellular portion of membrane-bound
379 FAS triggers an intracellular cascade resulting in apoptosis of the FAS-expressing cell. Apoptosis
380 is mediated by a 'death domain', an 85 amino acid-long structure in the intracellular portion of
381 FAS, encoded by exon nine³¹. In contrast, an isoform arising from skipping of exon 6 encodes a
382 secreted protein lacking the transmembrane domain. This soluble form of FAS acts as a decoy
383 receptor for FASL and therefore has biologically opposing actions to membrane-bound FAS, by
384 reducing FAS-FASL signalling and thus blocking the pro-apoptotic pathway²⁹.

385
386 Investigation of the mechanism underpinning the cis-pQTL for FAS revealed that the risk allele
387 for severe COVID-19 influences FAS mRNA splicing, resulting in a greater proportion of
388 transcripts lacking exon 6 (**Fig. 3b**), which in turn lead to more soluble FAS (**Supplementary Fig.**
389 **4**), the anti-apoptotic decoy receptor for FASL. Our data therefore support a model whereby
390 genetic predisposition to reduced FASL signalling through membrane-bound FAS leads to
391 increased risk of severe COVID-19 (**Fig. 3c**). We hypothesise that this may result in impaired
392 apoptosis of activated lymphocytes (enhancing immune-mediated pathology) or virus-infected
393 cells (retarding viral clearance). *In vitro*, treatment with ibrutinib, a Bruton's tyrosine kinase (BTK)
394 inhibitor used in the treatment of haematological malignancy, has been shown to decrease soluble
395 FAS, thereby enhancing FAS-mediated apoptosis³², suggesting a potential repurposing
396 opportunity for severe COVID-19. Interestingly, case reports describe clinical improvement in
397 haematology patients with severe COVID-19 on re-instigation of ibrutinib therapy^{33,34}.

398
399 *Fas* knock-out mice develop an autoimmune disease similar to human lupus, with anti-nuclear
400 antibodies, nephritis, lymphadenopathy and splenomegaly³⁵. Mirroring this, deleterious mutations
401 in the *FAS* gene in humans result in a rare Mendelian disease (autoimmune lymphoproliferative
402 syndrome, ALPS, OMIM: 601859), characterised by autoimmunity and lymphoproliferative
403 disease as a result of defective lymphocyte apoptosis^{36-38,39}. In addition, common variants in the
404 *FAS* gene region are associated with the proportion of lymphocytes in the blood white cell count⁴⁰,
405 chronic lymphocytic leukaemia (CLL)^{41,42}, and autoimmune diseases including juvenile idiopathic
406 arthritis (JIA)⁴³. The risk allele for JIA (rs7069750:C) reduces FAS gene expression.

407
408 These observations reveal striking parallels in the spectrum of immune-mediated disease
409 phenotypes related to genetic variation in *FAS*. Non-functional FAS protein (resulting from rare

410 coding mutations) and quantitatively reduced levels of FAS gene expression (due to common
411 non-coding polymorphisms) both predispose to autoimmune disease. Similarly, we show that
412 elevation of soluble FAS, which inhibits signalling via membrane-bound FAS, increases
413 susceptibility to severe COVID-19. Thus distinct genetic variants in the *FAS* gene converge on
414 impaired FASL-FAS signalling, and result in immunopathology.

415
416 Other studies have performed Mendelian randomisation of proteins in COVID-19^{44,45}. The MR
417 analysis of Zhou *et al* identified OAS1 as a causal factor common to COVID-19 susceptibility,
418 hospitalisation and very severe disease⁴⁴. In contrast, we identified FAS as contributing
419 specifically to severe COVID-19, but not susceptibility to infection. Gaziano *et al.*⁴⁵ identified
420 IFNAR2 and ACE2 as playing causal roles in COVID-19.

421
422 In summary, we demonstrate that that genetic tendency to higher levels of soluble FAS is a causal
423 factor in severe COVID. Moreover, we reveal a novel genetic mechanism by which the risk allele
424 for severe COVID-19 influences susceptibility through alternative splicing of FAS. This non-coding
425 variant affects alternative splicing, resulting in increased levels of soluble FAS, a decoy receptor
426 for FASL which blocks signalling of FASL via membrane-bound FAS on the cell surface. Our data
427 provide insights into the pathogenesis of severe COVID-19 and suggest a potential therapeutic
428 opportunity from restoration of FASL signalling.

429

430

431 **Methods**

432

433 **Mendelian Randomisation.**

434 Mendelian randomisation uses genetic variants as instrumental variables in order to investigate
435 the effects of a risk factor (exposure) on a disease (outcome), provided certain assumptions hold.
436 The method reduces bias created from confounding, by treating the variants used as equivalent
437 to treatment allocation in randomized control trials^{13,46-48}. We used two-sample Mendelian
438 Randomization (MR) to test the causal role of plasma proteins in severe COVID-19.

439

440 **Defining a list of proteins robustly associated with COVID-19 severity.**

441 We identified plasma proteins that were significantly associated (5% FDR) with COVID-19
442 severity in the two studies that used Olink proteomics platform (Filbin *et al.*¹⁰ and Gisby *et al.*¹¹).
443 To define a set of robust COVID-19 biomarkers, we took the intersect of the lists of significant
444 associations from these two studies. This resulted in 157 proteins.

445

446 **Identification of genetic instruments through pQTL mapping.**

447 To provide a set of genetic instruments for MR, we performed a meta-analysis of pQTL studies
448 through framework of the SCALLOP consortium. All contributing pQTL studies had been
449 performed using plasma with proteins measured using Olink immunoassays (Olink Bioscience,
450 Uppsala, Sweden).

451

452 **Cohort-level pQTL analysis.** Details of the cohorts and cohort-specific ethical approval are
453 included in the **Supplementary Table 2**. Plasma protein levels were measured using up to 5
454 Olink 92-plex immunoassays (“Inflammation”, “Cardiovascular2”, “Cardiovascular3”,
455 “Cardiometabolic” and “Immune Response”). Despite the nomenclature, inflammation and
456 immune related proteins were highly enriched on all panels. The sample size per protein across
457 all available cohorts varied from 3,658 (for proteins on the Immune Response panel) to 26,494
458 (from proteins on the cardiovascular2 and cardiovascular3 panels). All subjects were of European
459 heritage. Protein levels were rank-based inverse-normal transformed prior to genetic association
460 testing. Genome-wide association analyses were performed using an additive regression model
461 of protein on genotype with adjustment for age, sex and cohort specific covariates. Population
462 structure was accounted for using by including principal components as covariates or by
463 accounting for relatedness using linear mixed models as appropriate to the specific cohort.

464

465 **pQTL meta-analysis.** Prior to meta-analysis cohort-level summary statistics were quality
466 controlled EasyQC software⁴⁹, following the protocol as described in Winkler *et al.*⁴⁹. Meta-
467 analysis was performed using inverse-variance fixed effect method implemented in METAL⁵⁰
468 (‘STDERR’ option), followed by correction for genomic control. Meta-analysis summary statistics
469 were then further filtered for minor allele frequency (MAF) > 0.01, and heterogeneity in effect size
470 estimates. Variants with heterogeneity $I^2 \geq 75\%$ were not considered significant and were removed
471 prior to further analysis.

472

473 **pQTL locus definition.** To define the boundaries of each pQTL locus, we first selected all genetic
474 variants with $p\text{-value} < 1 \times 10^{-5}$ and then calculated the distance between each consecutive variant
475 located on the same chromosome. Two consecutive variants were identified as belonging to
476 different loci if they were more than 250 kb apart. The sentinel variant was defined as the variant
477 with the lowest p-value within the locus. A locus was defined as a cis-pQTL if the sentinel variant
478 was within 0.5 Mb of the start or end of the gene encoding the given protein, otherwise it was
479 classified as a trans-pQTL.

480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529

Outcome data for MR testing: COVID-19 GWAS.

We accessed COVID-19 GWAS data from the COVID-19 Host Genetics Initiative website (<https://www.covid19hg.org/>). To match the ancestry of the individuals in the pQTL meta-analysis, we downloaded data from European-ancestry individuals. Specifically, we downloaded the following datasets: European summary statistics without 23 and me data from the HGI website release 5 (release date 7th January 2021) for A2 (very severe respiratory confirmed COVID-19 versus population), B2 (hospitalised COVID-19 versus population), C2 (susceptibility - COVID-19 versus population). Prior to downstream analyses, all variants with heterogeneity p-value 0.001 (as per HGI recommendation) were removed. The following links were used to download the data: https://storage.googleapis.com/covid19-hg-public/20201215/results/20210107/COVID19_HGI_A2_ALL_eur_leave_ukbb_23andme_20210107.b37.txt.gz
https://storage.googleapis.com/covid19-hg-public/20201215/results/20210107/COVID19_HGI_B2_ALL_eur_leave_ukbb_23andme_20210107.b37.txt.gz
https://storage.googleapis.com/covid19-hg-public/20201215/results/20210107/COVID19_HGI_C2_ALL_eur_leave_ukbb_23andme_20210107.b37.txt.gz

The goal of our MR analysis was to test the causal role of proteins in very severe COVID-19 and so for our principal analyses we used the A2 COVID-19 GWAS dataset as the outcome. For FAS, the significant protein identified by our principal MR analysis (FAS), we also performed MR using COVID-19 dataset B2 and C2.

Details of MR testing.

Primary MR analysis. For each protein, MR evaluating its causal role in very severe COVID-19 was performed using the TwoSampleMR package⁵¹. Where a single variant was used as the genetic instrument, we performed a Wald Ratio (WR) test. In the case of multiple genetic variants, we used the fixed effects inverse variance weighted (IVW) method.

Variant selection. For each protein first we selected genetic variants associated with the protein level at genome-wide significance (P -value $< 5 \times 10^{-8}$). From these, we retained variants that were also present in the outcome (very severe COVID-19) GWAS summary statistics. Next, to obtain a set of genetic instruments with low correlation, we performed LD pruning of these variants using Plink 1.9⁵² and the options `clump_r2 = 0.01` and `clump_kb = 10,000`. The LD reference panel for the pruning procedure was created by randomly selecting 10,000 unrelated individuals of British ancestry (evaluated on the basis of genomic data) from UK Biobank, followed by removing positional and marker name duplicated SNPs from imputed genotypes using `--rm-dup exclude-all` function using Plink 2.0⁵². Variants in the MHC region (hg19 genome build chr6:26,000,000-34,000,000) were excluded.

Sensitivity analyses. Since MR relies on certain assumptions, that often cannot be directly evaluated, we performed a range of sensitivity analyses. We used statistical methods to test for horizontal pleiotropy including MR Egger⁵³. We performed MR using the weighted mode and median methods⁵⁴, which are more robust to the presence of horizontal pleiotropy, and the maximum likelihood (ML) method. The ML method allows for uncertainty in the effect size of the genetic associations with the exposure (unlike the IVW method which uses simple weights), and it allows for genetic associations with the exposure and with the outcome for each variant to be correlated⁵⁵.

530

531 *Cis-only MR.* As additional sensitivity analysis we repeated MR restricting the genetic
532 instruments to cis-pQTLs only, as these are less likely to be affected by horizontal pleiotropy²⁰.
533 To select cis-only instruments we performed LD pruning (as described earlier) on all variants
534 with $p < 5 \times 10^{-8}$ within a cis locus.

535

536 **Replication of FAS MR.**

537 The genetic instruments used in the primary analysis were pQTL identified in a meta-analysis of
538 studies that used Olink immunoassays. To validate this, we repeated the MR analysis for FAS
539 using an alternative pQTL dataset based on proteomic profiling using the aptamer-based
540 SomaLogic platform¹⁴. The COVID-19 GWAS data was the same as for the primary analysis (HGI
541 A2 GWAS summary statistics).

542

543 **Colocalisation.**

544 To distinguish causal relationships from confounding by LD we used colocalisation analysis.
545 Colocalisation analysis tests whether regional genetic association signals for different traits arise
546 from distinct or the same shared causal variant. The Bayesian colocalisation method implemented
547 in the `coloc.abf()` function from the “`coloc`”²¹ R package provides posterior probabilities (PP) for 5
548 different hypotheses: the null hypothesis of no association with either of the traits (H0) and four
549 alternative hypotheses of either association with only one of the traits (H1, H2), or association of
550 both traits but under the effect of distinct underlying causal variants (H3), or association of both
551 traits under the effect of a shared causal variant (H4) i.e. colocalisation. For candidate proteins
552 identified by the MR analysis, we compared the HGI A2 COVID-19 regional association signal(s)
553 with that of the relevant pQTL. We considered a $PP > 0.8$ as a strong evidence in favour of that
554 hypothesis.

555

556 We also used `coloc` to test whether the FAS cis-pQTL colocalised with eQTLs from multiple cell
557 types across multiple studies. These included multiple tissue types from GTEx v7 (obtained from
558 the GTEx Portal on 03/23/21), whole blood data from eQTLGen²⁴, and 5 sorted leukocyte subsets
559 from Peters *et al.*²⁵. An assumption of `coloc` is that there is at most one causal variant at the locus
560 per trait. To allow for the possibility of multiple independent eQTLs or pQTLs, we used the Sum
561 of Single Effects method²⁶, which allows for simultaneous colocalisation testing of multiple causal
562 variants.

563

564 **FAS levels in COVID-19 patients.**

565 We used data on COVID-19 patients and sex, age and ethnicity matched non-infected controls
566 from the study by Gisby *et al.*¹¹. The study design involved serial plasma sampling from the
567 COVID-19 patients. For full details of association testing see Gisby *et al.*¹¹. Briefly, differential
568 abundance analysis of FAS levels between COVID-19 patients and controls was performed using
569 linear mixed models with age, sex and ethnicity as covariates. Associations of FAS and clinical
570 severity scores were performed within COVID-19 cases, using a 4-level ordinal scale for clinical
571 severity (mild, moderate, severe and critical) at the time of blood sampling. Again, linear mixed
572 models were used to account for repeated measurements from the same individual.

573

574 **RNA-sequencing and splice QTL analysis.**

575 In 5,000 individuals of the INTERVAL cohort, 3 ml of whole blood were collected in Tempus Blood
576 RNA Tubes (ThermoFisher Scientific), following the manufacturer’s instructions. RNA extraction
577 was performed by QIAGEN Genomic Services using an in-house developed protocol based on
578 QIAGEN’s proprietary silica technology. We assessed the quality of the extracted RNA using
579 spectrophotometric analysis. RNA Integrity Number (RIN) values were determined using a

580 TapeStation 4200 system (Agilent), following the manufacturer's protocol. Messenger RNA
581 (mRNA) was isolated using a NEBNext Poly(A) mRNA Magnetic Isolation Module (NEB). Globin
582 depletion was performed using a KAPA RiboErase Globin Kit (Roche). RNA library preparation
583 was done using a NEBNext Ultra II DNA Library Prep Kit for Illumina (NEB) on a Bravo WS
584 automation system (Agilent). Libraries were pooled to 96-plex in equimolar amounts, quantified
585 using a High Sensitivity DNA Kit on a 2100 Bioanalyzer (Agilent), and then normalised to 2.8 nM
586 prior to sequencing. Samples were sequenced using 75 bp paired-end sequencing reads (reverse
587 stranded) on a NovaSeq 6000 system (S4 flow cell, Xp workflow; Illumina). We assessed the
588 sequence data quality using FastQC v0.11.8. Reads were aligned to the GRCh38 human
589 reference genome (Ensembl GTF annotation v99) using STAR v2.7.3.a⁵⁶. Data from 4,778
590 individuals were subjected to downstream analyses. We extracted transcript splice junctions with
591 the regtools "junction extract" tool, and introns were clustered and excision ratios calculated and
592 normalised for downstream sQTL analysis according to the leafcutter⁵⁷ pipeline (build #aa12b1e)
593 with default parameters. Cis-sQTLs were calculated on the resulting leafcutter ratios for the
594 excision event of FAS exon 6 (ENSE00003500194) and flanking introns, and genotypes with a
595 minor allele frequency >0.01 in the region +/- 200kb of the FAS gene using tensorQTL⁵⁸ 1.0.5.
596 Blood cell type proportions, sex, and 10 genomic and 10 splicing principal components were
597 added as covariates to the linear model.



598

599 **Supplementary Material**

600


601 **Supplementary Tables and Figures**

602



603
604 **Supplementary Figure 1:** MR estimates using different MR methods for 5 proteins significant in
605 the primary analysis (fixed effect inverse variance weighted method). a) MR effects estimated
606 from all variants (both cis and trans). b) MR effects estimated using only cis variants. Vertical
607 line represents odds ratio of 1.
608

609




610

611 **Supplementary Figure 2:** Genetic associations for TNFRSF10A and CCL2 plasma protein
 612 levels and very severe COVID-19 do not colocalise. **a)** The sentinel pQTL (rs13278062) for
 613 TNFRSF10A is in linkage equilibrium with the sentinel COVID-19 variant (rs1398232). The
 614 posterior probability of distinct causal variants from colocalisation testing (PP H3) = 0.87.

615 **b)** A trans-pQTL located on chromosome 3 (sentinel variant rs35728689) for CCL2 (which is
 616 encoded on chromosome 17) lies approximately 5kb upstream of the *CCR2* gene, which encodes
 617 the receptor for CCL2, suggesting an obvious biological mechanism for the trans-pQTL. Single-
 618 variant MR performed using this trans-pQTL was significant (rs35728689 $P=2.8 \times 10^{-2}$,
 619 Supplementary Table 1). However, LD r^2 between sentinel CCL2 pQTL (rs35728689) and sentinel
 620 COVID-19 variant (rs35081325) is 0.006 in 1000 genomes EUR population and the posterior
 621 probability of distinct causal variants from colocalisation testing (PP H3) = 1.0.


622

623




624
625 **Supplementary Figure 3:** Validation of MR estimates of the causal effect of soluble FAS
626 protein on COVID-19 outcomes. Genetic instruments were obtained from another pQTL study of
627 FAS levels measured with a different proteomic platform (SOMAScan¹⁴). Details of individual
628 instruments can be found in Supplementary Table 1. 'Olink' indicates the MR estimate obtained
629 in our analysis.

630
631
632
633



634
635 **Supplementary Figure 4:** Boxplot showing genotype at rs982764 versus plasma soluble FAS
636 levels (after correction for age, sex, batch effects, season of blood sampling and genetic
637 principal components) in the ORCADES cohort.

638



639
640
641
642
643
644
645
646
647
648

Supplementary Figure 5. Regional association plots for FAS pQTL and eQTL. Tracks from top to bottom: FAS plasma pQTL (SCALLOP meta-analysis), FAS eQTL in whole blood (eQTLGen) and lung (GTEx v7).

649

650 **Supplementary Tables (xlsx)**

651

652 **Supplementary Table 1: SNP-wise estimates of the MR effect.** All - overall MR estimate,
653 using all listed SNPs, exposure - protein levels, outcome - very severe COVID-19 (A2). genomic
654 positions based on human genome build GRCh37

655

656 **Supplementary Table 2:** Details of contributing cohorts

657

658

659 **Acknowledgements**

660 The proteomic work was carried out under the aegis of the SCALLOP consortium. We thank
661 Aikaterini Siopi for administrative assistance. We thank the UK Biobank resource, approved under
662 application 19655. Cohort-specific acknowledgements can be found in Supplementary Table 2.
663 J.F.W. and C.H, acknowledge support from the MRC Human Genetics Unit programme grant
664 “Quantitative traits in health and disease” (U.MC_UU_00007/10). J.E.P. acknowledges a UKRI
665 Innovation Fellowship at Health Data Research UK (MR/S004068/2), a UKRI-DHSC COVID-19
666 Rapid Response Rolling Call (MR/V027638/1) and Community Jameel and the Imperial
667 President’s Excellence Fund. The work of L.K. was supported by an RCUK Innovation Fellowship
668 from the National Productivity Investment Fund (MR/R026408/1). J.H.Z. is funded by the NIHR
669 Cambridge Biomedical Research Centre (BRC-1215-20014). A.L. is funded by the European
670 Union’s Horizon 2020 research and innovation program IMforFUTURE, under H2020-MSCA-ITN
671 grant agreement number 721815. B.P. is funded by a BHF Programme Grant (RG/18/13/33946).
672 D.Z. was supported by the AHA Postdoctoral Fellowship [19POST34370115]. C.K. was
673 supported by NHLBI contracts 75N92021D00001, 75N92021D00002, 75N92021D00003,
674 75N92021D00004, 75N92021D00005. J.F. was supported by the Dutch Heart Foundation IN-
675 CONTROL (CVON2018-27), the ERC Consolidator grant (101001678) and the Netherlands
676 Organ-on-Chip Initiative, an NWO Gravitation project (024.003.001) funded by the Ministry of
677 Education, Culture and Science of the government of The Netherlands’. N.M.C is a Wallenberg
678 Center for Molecular Medicine Fellow. A.R. is funded by R01 HL136574 and S10OD02868. C.He.
679 acknowledges the German Diabetes Center, (DDZ) which is funded by the German Federal
680 Ministry of Health (Berlin, Germany), the Ministry of Culture and Science of the state North Rhine-
681 Westphalia (Düsseldorf, Germany), and grants from the German Federal Ministry of Education
682 and Research (Berlin, Germany) to the German Center for Diabetes Research e.V. (DZD). D.V.Z
683 was supported by a VENI grant from NWO (194.006). J.G.S. was supported by grants from the
684 Swedish Heart-Lung Foundation (2016-0134, 2016-0315 and 2019-0526), the Swedish Research
685 Council (2017-02554), the European Research Council (ERC-STG-2015-679242), the Crafoord
686 Foundation, Skåne University Hospital, the Scania county, governmental funding of clinical
687 research within the Swedish National Health Service, a generous donation from the Knut and
688 Alice Wallenberg foundation to the Wallenberg Center for Molecular Medicine in Lund, and
689 funding from the Swedish Research Council (Linnaeus grant Dnr 349-2006-237, Strategic
690 Research Area Exodiab Dnr 2009-1039) and Swedish Foundation for Strategic Research (Dnr
691 IRC15-0067) to the Lund University Diabetes Center. J.D. holds a British Heart Foundation
692 Professorship and a NIHR Senior Investigator Award. K.M. is supported by grants from the
693 Swedish Research Council (grant no 2002-6147, 2005-6662, 2005-8214, 2008-2202, 2011-
694 02427, 2015-03257, 2017-00644, 2017-06100 and 2019-01291, grants from the Swedish
695 Research Council for Health, Working Life and Welfare (<https://forte.se/en/>; grant numbers 2011-
696 0346, and 2017-00721), and annual grants from Avtal om Läkarutbildning och Forskning (ALF;
697 Agreement concerning Cooperation on Medical Education and Research) between Uppsala
698 University and Uppsala County Council. He acknowledges the national research infrastructure
699 SIMPLER for provisioning of facilities and experimental support. SIMPLER receives funding

700 through the Swedish Research Council under the grant no 2017-00644. A.T. was supported by
701 the Wellcome Trust. K.S. was supported by the Biomedical Research Program at Weill Cornell
702 Medicine in Qatar, a program funded by the Qatar Foundation, and by multiple grants from the
703 Qatar National Research Fund (QNRF). C.L., E.W., and N.J.W. are funded by the Medical
704 Research Council (MC_UU_12015/1). NJW is a NIH Senior Investigator. R.J.S. is supported by
705 a UKRI Innovation- HDR-UK Fellowship (MR/S003061/1). T.L.A was supported by NIDDK/NIH
706 grant 1R01DK114183. J.K.B. acknowledges funding support from a BBSRC Institute Strategic
707 Programme Grant (BBS/E/D/20002172), UKRI (MC_PC_20004, MC_PC_19025, MC_PC_1905,
708 MRNO2995X/1) and the UK Intensive Care Society. RNA-sequencing in the INTERVAL study
709 was supported by the Wellcome Trust (grant reference 206194/Z/17/Z), NHSBT and
710 AstraZeneca. We thank the Sequencing Operations Team and Human Genetics Informatics
711 Team (Guillaume Noell and Vivek Iyer) at the Wellcome Sanger Institute for performing the RNA
712 library preparation and RNA-sequencing and analysis. EP is supported by the EU/EFPIA
713 Innovative Medicines Initiative Joint Undertaking BigData@Heart grant 116074. We thank Dr
714 Arianne Richard for helping with results interpretation and commenting on the manuscript.

715
716 Disclaimer: The views expressed in this manuscript are those of the authors and do not
717 necessarily represent the views of the National Heart, Lung, and Blood Institute; the National
718 Institutes of Health; or the U.S. Department of Health and Human Services. The views expressed
719 are those of the author(s) and not necessarily those of the NIH or the Department of Health and
720 Social Care.

721

722

723 **References**

724

725

- 726 1. Szabo, P.A., *et al.* Longitudinal profiling of respiratory and systemic immune responses
727 reveals myeloid cell-driven lung inflammation in severe COVID-19. *Immunity* (2021).
- 728 2. Wichmann, D., *et al.* Autopsy Findings and Venous Thromboembolism in Patients With
729 COVID-19: A Prospective Cohort Study. *Ann Intern Med* **173**, 268-277 (2020).
- 730 3. Carvalho, T., Krammer, F. & Iwasaki, A. The first 12 months of COVID-19: a timeline of
731 immunological insights. *Nature Reviews Immunology* (2021).
- 732 4. Arunachalam, P.S., *et al.* Systems biological assessment of immunity to mild versus severe
733 COVID-19 infection in humans. *Science* **369**, 1210 (2020).
- 734 5. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *New England*
735 *Journal of Medicine* (2021).
- 736 6. Horby, P.W., *et al.* Tocilizumab in patients admitted to hospital with COVID-19
737 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial.
738 *medRxiv*, 2021.2002.2011.21249258 (2021).
- 739 7. Dexamethasone in Hospitalized Patients with Covid-19. *New England Journal of Medicine*
740 **384**, 693-704 (2020).
- 741 8. McInnes, I.B., Buckley, C.D. & Isaacs, J.D. Cytokines in rheumatoid arthritis — shaping
742 the immunological landscape. *Nature Reviews Rheumatology* **12**, 63-68 (2016).
- 743 9. Attwood, M.M., Jonsson, J., Rask-Andersen, M. & Schiöth, H.B. Soluble ligands as drug
744 targets. *Nature Reviews Drug Discovery* **19**, 695-710 (2020).
- 745 10. Filbin, M.R., *et al.* Plasma proteomics reveals tissue-specific cell death and mediators of
746 cell-cell interactions in severe COVID-19 patients. *bioRxiv : the preprint server for*
747 *biology*, 2020.2011.2002.365536 (2020).

- 748 11. Gisby, J., *et al.* Longitudinal proteomic profiling of dialysis patients with COVID-19
749 reveals markers of severity and predictors of death. *eLife* **10**, e64827 (2021).
- 750 12. Hingorani, A. & Humphries, S. Nature's randomised trials. *The Lancet* **366**, 1906-1908
751 (2005).
- 752 13. Burgess, S., *et al.* Using published data in Mendelian randomization: a blueprint for
753 efficient identification of causal risk factors. *European journal of epidemiology* **30**, 543-
754 552 (2015).
- 755 14. Sun, B.B., *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73-79 (2018).
- 756 15. Folkersen, L., *et al.* Genomic and drug target evaluation of 90 cardiovascular proteins in
757 30,931 individuals. *Nature Metabolism* **2**, 1135-1148 (2020).
- 758 16. Folkersen, L., *et al.* Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular
759 disease. *PLoS Genetics* **13**, 1-21 (2017).
- 760 17. The, C.-H.G.I. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the
761 role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus
762 pandemic. *European Journal of Human Genetics* **28**, 715-718 (2020).
- 763 18. Greenland, S. An introduction to instrumental variables for epidemiologists. *International*
764 *Journal of Epidemiology* **29**, 722-729 (2000).
- 765 19. Davey Smith, G. & Ebrahim, S. 'Mendelian randomization': can genetic epidemiology
766 contribute to understanding environmental determinants of disease?*. *International*
767 *Journal of Epidemiology* **32**, 1-22 (2003).
- 768 20. Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal
769 inference in epidemiological studies. *Human Molecular Genetics* **23**, R89-R98 (2014).
- 770 21. Giambartolomei, C., *et al.* Bayesian Test for Colocalisation between Pairs of Genetic
771 Association Studies Using Summary Statistics. *PLOS Genetics* **10**, e1004383 (2014).
- 772 22. Staley, J.R., *et al.* PhenoScanner: a database of human genotype–phenotype associations.
773 *Bioinformatics* **32**, 3207-3209 (2016).
- 774 23. Kamat, M.A., *et al.* PhenoScanner V2: an expanded tool for searching human genotype–
775 phenotype associations. *Bioinformatics* **35**, 4851-4853 (2019).
- 776 24. Võsa, U., *et al.* Unraveling the polygenic architecture of complex traits using blood eQTL
777 metaanalysis. *bioRxiv*, 447367 (2018).
- 778 25. Peters, J.E., *et al.* Insight into Genotype-Phenotype Associations through eQTL Mapping
779 in Multiple Cell Types in Health and Immune-Mediated Disease. *Plos Genetics* **12**(2016).
- 780 26. Wallace, C. A more accurate method for colocalisation analysis allowing for multiple
781 causal variants. *bioRxiv*, 2021.2002.2023.432421 (2021).
- 782 27. Baeza-Centurion, P., Minana, B., Schmiedel, J.M., Valcarcel, J. & Lehner, B.
783 Combinatorial Genetics Reveals a Scaling Law for the Effects of Mutations on Splicing.
784 *Cell* **176**, 549-563 e523 (2019).
- 785 28. Paronetto, M.P., Passacantilli, I. & Sette, C. Alternative splicing and cell survival: from
786 tissue homeostasis to disease. *Cell Death Differ* **23**, 1919-1929 (2016).
- 787 29. Cascino, I., Fiucci, G., Papoff, G. & Ruberti, G. Three functional soluble forms of the
788 human apoptosis-inducing Fas molecule are produced by alternative splicing. *J Immunol*
789 **154**, 2706-2713 (1995).
- 790 30. Meynier, S. & Rieux-Laucat, F. FAS and RAS related Apoptosis defects: From
791 autoimmunity to leukemia. *Immunol Rev* **287**, 50-61 (2019).
- 792 31. Strasser, A., Jost, P.J. & Nagata, S. The Many Roles of FAS Receptor Signaling in the
793 Immune System. *Immunity* **30**, 180-192 (2009).

- 794 32. Sehgal, L., *et al.* FAS-antisense 1 lncRNA and production of soluble versus membrane Fas
795 in B-cell lymphoma. *Leukemia* **28**, 2376-2387 (2014).
- 796 33. Lin, A.Y., Cuttica, M.J., Ison, M.G. & Gordon, L.I. Ibrutinib for chronic lymphocytic
797 leukemia in the setting of respiratory failure from severe COVID-19 infection: Case report
798 and literature review. *eJHaem* **1**, 596-600 (2020).
- 799 34. Treon, S.P., *et al.* The BTK inhibitor ibrutinib may protect against pulmonary injury in
800 COVID-19-infected patients. *Blood* **135**, 1912-1915 (2020).
- 801 35. Watanabe-Fukunaga, R., Brannan, C.I., Copeland, N.G., Jenkins, N.A. & Nagata, S.
802 Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates
803 apoptosis. *Nature* **356**, 314-317 (1992).
- 804 36. Fisher, G.H., *et al.* Dominant interfering Fas gene mutations impair apoptosis in a human
805 autoimmune lymphoproliferative syndrome. *Cell* **81**, 935-946 (1995).
- 806 37. Rieux-Laucat, F., *et al.* Mutations in Fas associated with human lymphoproliferative
807 syndrome and autoimmunity. *Science* **268**, 1347-1349 (1995).
- 808 38. Kuehn, H.S., *et al.* FAS Haploinsufficiency Is a Common Disease Mechanism in the
809 Human Autoimmune Lymphoproliferative Syndrome. *The Journal of Immunology* **186**,
810 6035 (2011).
- 811 39. Price, S., *et al.* Natural history of autoimmune lymphoproliferative syndrome associated
812 with FAS gene mutations. *Blood* **123**, 1989-1999 (2014).
- 813 40. Vuckovic, D., *et al.* The Polygenic and Monogenic Basis of Blood Traits and Diseases.
814 *Cell* **182**, 1214-1231 e1211 (2020).
- 815 41. Berndt, S.I., *et al.* Genome-wide association study identifies multiple risk loci for chronic
816 lymphocytic leukemia. *Nature Genetics* **45**, 868-876 (2013).
- 817 42. Berndt, S.I., *et al.* Meta-analysis of genome-wide association studies discovers multiple
818 loci for chronic lymphocytic leukemia. *Nat Commun* **7**, 10933 (2016).
- 819 43. Hinks, A., *et al.* Dense genotyping of immune-related disease regions identifies 14 new
820 susceptibility loci for juvenile idiopathic arthritis. *Nat Genet* **45**, 664-669 (2013).
- 821 44. Zhou, S., *et al.* A Neanderthal OAS1 isoform protects individuals of European ancestry
822 against COVID-19 susceptibility and severity. *Nature Medicine* (2021).
- 823 45. Gaziano, L., *et al.* Actionable druggable genome-wide Mendelian randomization identifies
824 repurposing opportunities for COVID-19. *medRxiv*, 2020.2011.2019.20234120 (2020).
- 825 46. Burgess, S., Thompson, S.G. & Collaboration, C.C.G. Methods for meta-analysis of
826 individual participant data from Mendelian randomisation studies with binary outcomes.
827 *Stat Methods Med Res* **25**, 272-293 (2016).
- 828 47. Fortune, M.D., *et al.* Statistical colocalization of genetic risk variants for related
829 autoimmune diseases in the context of common controls. *Nature Genetics* **47**, 839-846
830 (2015).
- 831 48. Davies, N.M., *et al.* The many weak instruments problem and Mendelian randomization.
832 *Statistics in Medicine* **34**, 454-468 (2015).
- 833 49. Winkler, T.W., *et al.* Quality control and conduct of genome-wide association meta-
834 analyses. *Nature protocols* **9**, 1192-1212 (2014).
- 835 50. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: Fast and efficient meta-analysis of
836 genomewide association scans. *Bioinformatics* **26**, 2190-2191 (2010).
- 837 51. Hemani, G., *et al.* The MR-Base platform supports systematic causal inference across the
838 human phenome. *eLife* **7**, e34408 (2018).

- 839 52. Chang, C.C., *et al.* Second-generation PLINK: rising to the challenge of larger and richer
840 datasets. *GigaScience* **4**, 7-7 (2015).
- 841 53. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
842 instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*
843 **44**, 512-525 (2015).
- 844 54. Qingyuan, Z., Jingshu, W., Gibran, H., Jack, B. & Dylan, S.S. Statistical inference in two-
845 sample summary-data Mendelian randomization using robust adjusted profile score. *The*
846 *Annals of Statistics* **48**, 1742-1769 (2020).
- 847 55. Burgess, S., Butterworth, A. & Thompson, S.G. Mendelian Randomization Analysis With
848 Multiple Genetic Variants Using Summarized Data. *Genetic Epidemiology* **37**, 658-665
849 (2013).
- 850 56. Dobin, A., *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21
851 (2013).
- 852 57. Li, Y.I., *et al.* Annotation-free quantification of RNA splicing using LeafCutter. *Nature*
853 *Genetics* **50**, 151-158 (2018).
- 854 58. Taylor-Weiner, A., *et al.* Scaling computational genomics to millions of individuals with
855 GPUs. *Genome Biology* **20**, 228 (2019).
- 856